Jacobs Levy Equity Management’s Caribou Biosciences CRBU Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$682K	Sell	358,941 -465,358	-56%	-$799K	﹤0.01%	773
2025 Q4	$1.31M	Buy	824,299 +475,216	+136%	+$997K	0.01%	644
2025 Q3	$813K	Sell	349,083 -607,897	-64%	-$1.15M	﹤0.01%	755
2025 Q2	$1.21M	Sell	956,980 -485,141	-34%	-$477K	﹤0.01%	722
2025 Q1	$1.32M	Buy	1,442,121 +234,052	+19%	+$304K	0.01%	756
2024 Q4	$1.92M	Buy	+1,208,069	New	+$2.43M	0.01%	598
2023 Q3	–	Sell	-436,024	Closed	-$1.85M	–	982
2023 Q2	$1.85M	Buy	436,024 +403,804	+1,253%	+$1.81M	0.01%	588
2023 Q1	$171K	Buy	+32,220	New	+$201K	﹤0.01%	913

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's CRBU Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Caribou Biosciences (CRBU) stake by 56% in Q1 2026, selling an estimated $799K and leaving 358,941 shares worth $682K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Jacobs Levy Equity Management first reported a position in CRBU in Q1 2023 and has held it in 8 quarters since. The position peaked at $1.92M in Q4 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Jacobs Levy Equity Management held 358,941 shares of Caribou Biosciences worth $682K as of Q1 2026.
Jacobs Levy Equity Management sold 465,358 Caribou Biosciences shares in Q1 2026, an estimated $799K.
Caribou Biosciences made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #773 holding.
Jacobs Levy Equity Management first reported a position in Caribou Biosciences in Q1 2023 and has held it in 8 quarters since.
Jacobs Levy Equity Management's Caribou Biosciences position peaked at $1.92M in Q4 2024.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.